Veracyte, Inc. (VCYT) is a Healthcare stock trading at $56.60 (as of 2026-07-24), with a market capitalization of $4.52B and a trailing P/E of 51.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Veracyte develops and sells genomic diagnostic tests (for cancers and lung diseases), and it generates revenue primarily from testing, as reflected by its Testing Revenue line and test-volume operating metrics.
Veracyte's profit model is driven by a testing workflow, where operating performance depends on how many tests are performed and reported (Testing Volume, Testing Tests Reported, and Testing Tests Delivered), which flows into Testing Revenue.
| Total | $0.1B |
Business quality (Solid): Clear, volume-based testing model supported by multiple genomic assays across several clinical areas, but the provided data shows revenue concentration in testing (product revenue is shown as 0 in the candidates), so results can be sensitive to test activity.
Valuation: At 44× earnings, VCYT trades 75% above the Healthcare Services average (25×). Note: one-time items can distort reported P/E.
| Price | $56.60 |
| Market Cap | $4.52B |
| P/E Ratio | 51.3 |
| EV / EBITDA | 42.9 |
| Price / Book | 3.36 |
| Price / Sales | 8.34 |
| FCF Yield | 3.4% |
| DCF Value (model) | $12.48 |
| DCF Upside vs Price | -78.0% |
| Revenue (TTM) | $517.14M |
| Net Margin | 12.8% |
| Revenue Growth (YoY) | 21.5% |
| EPS Growth (YoY) | 300.0% |
| FCF Growth (YoY) | 810.3% |
| Altman Z-Score | 28.47 (safe) |
| Stock P/E | 51.3 |
| Sector P/E (Healthcare) | 21.2 |
| Industry P/E (Healthcare Services) | 27.9 |
| vs Sector | 141.7% |
| vs Industry | 84.2% |
| Top Institutional Holder | BlackRock, Inc. ($424.29M) |
| Institutional Holders Tracked | 10 |
| Congressional Trades (recent) | 10 |
| Sector | Healthcare |
| Industry | Healthcare Services |
| CEO | Marc A. Stapley |
| Employees | 824 |
| Country | US |
| IPO Date | 2013-10-30 |
Data as of 2026-07-24.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.